Cape Investment Advisory’s iShares US Medical Devices ETF IHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.48K Buy
+30
New +$1.52K ﹤0.01% 1283
2026
Q1
Sell
-30
Closed -$1.86K 668
2025
Q4
$1.86K Hold
30
﹤0.01% 1118
2025
Q3
$1.8K Hold
30
﹤0.01% 690
2025
Q2
$1.88K Hold
30
﹤0.01% 950
2025
Q1
$1.81K Hold
30
﹤0.01% 905
2024
Q4
$1.75K Hold
30
﹤0.01% 896
2024
Q3
$1.78K Hold
30
﹤0.01% 838
2024
Q2
$1.68K Hold
30
﹤0.01% 803
2024
Q1
$1.76K Sell
30
-365
-92% -$20.6K ﹤0.01% 782
2023
Q4
$21.3K Buy
395
+365
+1,217% +$17.8K 0.01% 520
2023
Q3
$1.46K Hold
30
﹤0.01% 812
2023
Q2
$1.69K Hold
30
﹤0.01% 790
2023
Q1
$1.62K Buy
+30
New +$1.6K ﹤0.01% 834

Other funds holding IHI

Cape Investment Advisory's IHI Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in iShares US Medical Devices ETF (IHI) in Q2 2026: 30 shares worth $1.48K. The stake represents ﹤0.01% of the portfolio and ranks #1283 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in IHI as recently as Q4 2025.

Cape Investment Advisory first reported a position in IHI in Q1 2023 and has held it in 13 quarters since. The position peaked at $21.3K in Q4 2023. 500 funds tracked by Wall St. Rank hold IHI as of Q2 2026.

  • Cape Investment Advisory held 30 shares of iShares US Medical Devices ETF worth $1.48K as of Q2 2026.
  • iShares US Medical Devices ETF was a new Cape Investment Advisory position in Q2 2026.
  • iShares US Medical Devices ETF made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1283 holding.
  • Cape Investment Advisory first reported a position in iShares US Medical Devices ETF in Q1 2023 and has held it in 13 quarters since.
  • Cape Investment Advisory's iShares US Medical Devices ETF position peaked at $21.3K in Q4 2023.
  • 500 funds tracked by Wall St. Rank held iShares US Medical Devices ETF as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.